OKLAHOMA CITY -- (Business Wire)

The law firm of Federman & Sherwood has launched an investigation into Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (“Salix”) for possible violations of federal securities laws.

On January 28, 2015 the Company’s audit committee announced that the consolidated financial statements for the full year 2013 and the first three quarters of 2014 require correction of certain errors and they should no longer be relied upon. The errors were primarily associated with the timing of recognition of certain revenue, revenue-reducing returns and discounts, and expenses, on previously reported net income or loss after income taxes of each of these periods.

If you currently own Salix common stock and purchased it prior to January 28, 2015 or have information to assist in our investigation; or, have any questions or concerns regarding this notice or preservation of your rights, please contact our office. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.

Contacts:

Federman & Sherwood
Robin Hester, 405-235-1560
rkh@federmanlaw.com

Source: Federman & Sherwood